Motor Neurone Disease (MND) is a condition that progresses very quickly. After diagnosis, people with MND usually live for only two to three years. This disease damages nerve cells that control movement, leading to muscle weakness, paralysis, and breathing problems. For a long time, scientists have been trying to find a way to slow down this process. Now, researchers in Australia think they have found a way to reduce the damage.
A team at the University of Queensland has created a new drug. Their research, published in the journal Molecular Cell, shows that this drug targets a specific immune receptor called C5aR2. Previous attempts by other drug developers to interact with this receptor had failed. This receptor is found on the surface of many immune cells and is important for the body's inflammation response.
Professor Trent Woodruff, who is leading the research, explained that this receptor was difficult to target because it does not work like most other receptors. "This allowed us to see the structure and function of the receptor which led to the discovery that C5aR2 does not behave like most other receptors," Woodruff said. "It is unable to couple to G proteins, a rare and important distinction which explains why it's been so difficult to target and why its role in inflammation has been so elusive."
The scientists created a special molecule called R8Y. This compound attaches directly to the C5aR2 receptor. The main goal is to decrease the severe inflammation that makes neurodegenerative diseases like MND so aggressive. The drug aims to slow the disease's progression by reducing inflammation.
This discovery was the result of a large international collaboration. Researchers from Australia worked with experts from institutions in India, Japan, and South Korea. They created a detailed model of how the drug connects to the receptor. This helped them understand how the signals work. The project received funding from the National Health and Medical Research Council and the nonprofit organization FightMND.
The researchers believe that a drug based on this discovery could be tested in human trials within five years. If successful, it could change MND from a rapidly fatal illness into a long-term manageable condition, giving patients more time.